Ryvu Therapeutics receives approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Spain
Ryvu Therapeutics Presents Clinical and Translational Data Updates at the 63rd American Society of Hematology (ASH) Annual Meeting and the 44th San Antonio Breast Cancer Symposium